With 20 blockbuster launches, Novartis CEO Narasimhan hopes to overcome a $9 billion patent cliff.
Summary- Leading the charge for Narasimhan’s blockbuster launch list is cholesterol therapy Leqvio, which awaits an FDA decision on Jan. 1. Others…
Summary- Leading the charge for Narasimhan’s blockbuster launch list is cholesterol therapy Leqvio, which awaits an FDA decision on Jan. 1. Others…